FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292379242> ?p ?o ?g. }

• W4292379242 endingPage "100724" @default.
• W4292379242 startingPage "100724" @default.
• W4292379242 abstract "Although exome sequencing has a greater overall diagnostic yield than targeted gene panels in the evaluation of nonimmune hydrops fetalis and fetal effusions, the cost-effectiveness of this approach is not known.This study aimed to evaluate the costs and outcomes of targeted gene panels vs exome sequencing for prenatally diagnosed nonimmune hydrops fetalis and fetal effusions when next-generation sequencing is pursued following nondiagnostic standard nonimmune hydrops fetalis evaluations, including karyotype or chromosomal microarray.A decision-analytical model was designed using TreeAge Pro to compare 10 genetic testing strategies, including a single test only (RASopathy, metabolic, or nonimmune hydrops fetalis-targeted gene panel or exome sequencing), sequential testing (RASopathy panel followed by nonimmune hydrops fetalis panel, metabolic panel followed by nonimmune hydrops fetalis panel, RASopathy panel followed by exome sequencing, metabolic panel followed by exome sequencing, and nonimmune hydrops fetalis panel followed by exome sequencing), and no additional genetic testing. Our theoretical cohort included cases with normal karyotype and/or microarray and excluded cases of alloimmunization and congenital viral infections. As nonimmune hydrops fetalis and fetal effusions can present throughout gestation, whereas pregnancy management options vary depending on gestational age, outcomes were calculated for 3 time intervals: 10 to 18, 18 to 22, and >22 weeks of gestation. The primary outcome was incremental cost per quality-adjusted life year. Additional outcomes included termination of pregnancy, stillbirth, neonatal death, and neonates born with mild, moderate, and severe or profound disease phenotypes. The cost-effectiveness threshold was $100,000 per quality-adjusted life year.Among women <18 weeks of gestation, exome sequencing alone was the dominant strategy associated with the lowest costs ($221 million) and the highest quality-adjusted life years (10,288). Strategies with exome sequencing alone or as a sequential test resulted in more terminations but fewer stillbirths, neonatal deaths (NNDs), and affected infants than strategies without exome sequencing. Among women between 18 and 22 weeks of gestation, exome sequencing alone was also associated with the lowest costs ($188 million) and the highest quality-adjusted life years (8734), and similar trends were observed in pregnancy outcomes. Among patients >22 weeks of gestations, when termination was not available, exome sequencing was associated with lower costs ($300 million) and the highest quality-adjusted life years (8492). Exome sequencing was cost-effective up to a cost per test of $50,451 at <18 weeks of gestation, $50,423 at 18 to 22 weeks of gestation, and $9530 at >22 weeks of gestation. Targeted genetic panels and exome sequencing were cost-effective strategies compared with no additional genetic testing.For cases of nonimmune hydrops fetalis and fetal effusions with nondiagnostic karyotype or microarray, next-generation sequencing was cost-effective compared with a strategy without additional genetic testing. For those that undergo next-generation sequencing, exome sequencing was the cost-effective strategy compared with all other testing strategies using targeted gene panels, leading to lower costs and fewer adverse perinatal outcomes. Exome sequencing was cost-effective in a setting without the option for pregnancy termination. These data supported the routine use of exome sequencing when next-generation sequencing is pursued for establishing a genetic diagnosis underlying otherwise unexplained nonimmune hydrops fetalis and fetal effusions." @default.
• W4292379242 created "2022-08-20" @default.
• W4292379242 creator A5006906657 @default.
• W4292379242 creator A5027635629 @default.
• W4292379242 creator A5052298622 @default.
• W4292379242 creator A5060737880 @default.
• W4292379242 date "2022-11-01" @default.
• W4292379242 modified "2023-10-14" @default.
• W4292379242 title "Cost-Effectiveness of Exome Sequencing versus Targeted Gene Panels for Prenatal Diagnosis of Fetal Effusions and Non-Immune Hydrops Fetalis" @default.
• W4292379242 cites W1614178986 @default.
• W4292379242 cites W1978278616 @default.
• W4292379242 cites W1980703646 @default.
• W4292379242 cites W1987106585 @default.
• W4292379242 cites W1988996860 @default.
• W4292379242 cites W1989125711 @default.
• W4292379242 cites W1992511976 @default.
• W4292379242 cites W1998627165 @default.
• W4292379242 cites W1999474375 @default.
• W4292379242 cites W2007518585 @default.
• W4292379242 cites W2030855498 @default.
• W4292379242 cites W2033799138 @default.
• W4292379242 cites W2034290326 @default.
• W4292379242 cites W2078580691 @default.
• W4292379242 cites W2079712925 @default.
• W4292379242 cites W2089619223 @default.
• W4292379242 cites W2105828479 @default.
• W4292379242 cites W2123141501 @default.
• W4292379242 cites W2136818027 @default.
• W4292379242 cites W2149027091 @default.
• W4292379242 cites W2162812705 @default.
• W4292379242 cites W2205081658 @default.
• W4292379242 cites W2328833893 @default.
• W4292379242 cites W2585057233 @default.
• W4292379242 cites W2614358713 @default.
• W4292379242 cites W2743843765 @default.
• W4292379242 cites W2800239415 @default.
• W4292379242 cites W2895296468 @default.
• W4292379242 cites W2899549733 @default.
• W4292379242 cites W2910583407 @default.
• W4292379242 cites W2912938672 @default.
• W4292379242 cites W2921548951 @default.
• W4292379242 cites W2922322238 @default.
• W4292379242 cites W2943310425 @default.
• W4292379242 cites W2945827666 @default.
• W4292379242 cites W3001013727 @default.
• W4292379242 cites W3014218370 @default.
• W4292379242 cites W3019341832 @default.
• W4292379242 cites W3031205622 @default.
• W4292379242 cites W3091850289 @default.
• W4292379242 cites W3107801930 @default.
• W4292379242 cites W3153578041 @default.
• W4292379242 cites W3183496013 @default.
• W4292379242 cites W807075596 @default.
• W4292379242 doi "https://doi.org/10.1016/j.ajogmf.2022.100724" @default.
• W4292379242 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35995366" @default.
• W4292379242 hasPublicationYear "2022" @default.
• W4292379242 type Work @default.
• W4292379242 citedByCount "1" @default.
• W4292379242 countsByYear W42923792422023 @default.
• W4292379242 crossrefType "journal-article" @default.
• W4292379242 hasAuthorship W4292379242A5006906657 @default.
• W4292379242 hasAuthorship W4292379242A5027635629 @default.
• W4292379242 hasAuthorship W4292379242A5052298622 @default.
• W4292379242 hasAuthorship W4292379242A5060737880 @default.
• W4292379242 hasConcept C104317684 @default.
• W4292379242 hasConcept C10590036 @default.
• W4292379242 hasConcept C126322002 @default.
• W4292379242 hasConcept C131872663 @default.
• W4292379242 hasConcept C16671776 @default.
• W4292379242 hasConcept C2777674756 @default.
• W4292379242 hasConcept C2779234561 @default.
• W4292379242 hasConcept C2780673598 @default.
• W4292379242 hasConcept C46973012 @default.
• W4292379242 hasConcept C501734568 @default.
• W4292379242 hasConcept C54355233 @default.
• W4292379242 hasConcept C71924100 @default.
• W4292379242 hasConcept C86803240 @default.
• W4292379242 hasConceptScore W4292379242C104317684 @default.
• W4292379242 hasConceptScore W4292379242C10590036 @default.
• W4292379242 hasConceptScore W4292379242C126322002 @default.
• W4292379242 hasConceptScore W4292379242C131872663 @default.
• W4292379242 hasConceptScore W4292379242C16671776 @default.
• W4292379242 hasConceptScore W4292379242C2777674756 @default.
• W4292379242 hasConceptScore W4292379242C2779234561 @default.
• W4292379242 hasConceptScore W4292379242C2780673598 @default.
• W4292379242 hasConceptScore W4292379242C46973012 @default.
• W4292379242 hasConceptScore W4292379242C501734568 @default.
• W4292379242 hasConceptScore W4292379242C54355233 @default.
• W4292379242 hasConceptScore W4292379242C71924100 @default.
• W4292379242 hasConceptScore W4292379242C86803240 @default.
• W4292379242 hasFunder F4320306134 @default.
• W4292379242 hasFunder F4320314520 @default.
• W4292379242 hasFunder F4320319458 @default.
• W4292379242 hasFunder F4320332161 @default.
• W4292379242 hasIssue "6" @default.
• W4292379242 hasLocation W42923792421 @default.
• W4292379242 hasLocation W42923792422 @default.
• W4292379242 hasOpenAccess W4292379242 @default.

• next